Bristol-Myers Decries Blue Cross Unit's Last-Minute Dropout

By Bryan Koenig · December 5, 2023, 5:06 PM EST

Celgene and parent Bristol-Myers Squibb expressed frustration Tuesday about the timing of a Blue Cross unit's decision to bow out as a plaintiff in New Jersey federal court antitrust litigation accusing...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Letter

Case Information

Case Title

IN RE REVLIMID & THALOMID PURCHASER ANTITRUST LITIGATION

Case Number

Court

New Jersey

Nature of Suit

Anti-Trust

Date Filed

March 01, 2019

Recent Articles By Bryan

November 15, 2024
PBMs Denied Breakup Of Combined FTC Insulin Price Trial
November 13, 2024
Outgoing DOJ Antitrust Head Wants To Unstack Healthcare
November 12, 2024
HIV Drug Buyers Want Gilead Product Switch Claims Revived
November 12, 2024
Unsatisfied With $70M UTC Win, Sandoz Appeals To 3rd Circ.
November 07, 2024
Same PBM Conduct Means Same Insulin Price Trial, FTC Says
October 21, 2024
PBMs Keep Door Open To Constitutional Riposte Against FTC
October 16, 2024
Caremark, Optum Say FTC Insulin Case Gets PBMs All Wrong
October 15, 2024
'Extraordinary' Blue Cross Deal Includes $2.8B Payout
October 07, 2024
Merck Immune For 'Inflated' Vax Claims To FDA, 3rd Circ. Says
September 06, 2024
Actelion Must Face Tracleer Antitrust Suit With Class Certified